RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adamis Pharmaceuticals Stock

Adamis Pharmaceuticals Net Income 2024

Adamis Pharmaceuticals Net Income

6.12 M USD

Ticker

ADMP

ISIN

US00547W2089

WKN

A1XA2F

In 2024, Adamis Pharmaceuticals's profit amounted to 6.12 M USD, a -180% increase from the -7.65 M USD profit recorded in the previous year.

The Adamis Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2026e1.97
2025e3.43
2024e6.12
2023e-7.65
2022-26.48
2021-45.83
2020-49.39
2019-27.51
2018-39.01
2017-25.54
2016-20.81
2015-13.57
2014-9.32
2013-8.16
2012-7.19
2011-4.92
2010-6.98
2009-6.71
2008-1.53
2007-1.93
20069.67
2005-5.01
2004-28.15
2003-13.53

Adamis Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Adamis Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adamis Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adamis Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Adamis Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Adamis Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Adamis Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adamis Pharmaceuticals’s growth potential.

Adamis Pharmaceuticals Revenue, EBIT and net profit per share

DateAdamis Pharmaceuticals RevenueAdamis Pharmaceuticals EBITAdamis Pharmaceuticals Net Income
2026e148.02 M USD2.12 M USD1.97 M USD
2025e71.34 M USD3.75 M USD3.43 M USD
2024e35.07 M USD6.75 M USD6.12 M USD
2023e17.53 M USD-10.54 M USD-7.65 M USD
20224.76 M USD-25.06 M USD-26.48 M USD
20212.21 M USD-32.07 M USD-45.83 M USD
20202.78 M USD-31.68 M USD-49.39 M USD
201922.11 M USD-29.03 M USD-27.51 M USD
201815.09 M USD-39.45 M USD-39.01 M USD
201713.07 M USD-24.69 M USD-25.54 M USD
20166.47 M USD-25.2 M USD-20.81 M USD
20150 USD-13.85 M USD-13.57 M USD
20140 USD-8.1 M USD-9.32 M USD
20130 USD-4.4 M USD-8.16 M USD
20120 USD-3.22 M USD-7.19 M USD
20110 USD-4.82 M USD-4.92 M USD
20100 USD-6.24 M USD-6.98 M USD
2009290,000 USD-3.98 M USD-6.71 M USD
20080 USD-1.32 M USD-1.53 M USD
20070 USD-1.83 M USD-1.93 M USD
20062.66 M USD-4.68 M USD9.67 M USD
200512.2 M USD-5.36 M USD-5.01 M USD
20042.03 M USD-14 M USD-28.15 M USD
20031.62 M USD-13.89 M USD-13.53 M USD

Adamis Pharmaceuticals stock margins

The Adamis Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adamis Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adamis Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Adamis Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Adamis Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Adamis Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Adamis Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adamis Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adamis Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adamis Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Adamis Pharmaceuticals Margin History

Adamis Pharmaceuticals Gross marginAdamis Pharmaceuticals Profit marginAdamis Pharmaceuticals EBIT marginAdamis Pharmaceuticals Profit margin
2026e-30.1 %1.43 %1.33 %
2025e-30.1 %5.25 %4.81 %
2024e-30.1 %19.26 %17.45 %
2023e-30.1 %-60.14 %-43.64 %
2022-30.1 %-526.88 %-556.72 %
2021-211.14 %-1,451.97 %-2,074.91 %
2020-127.87 %-1,140.96 %-1,778.84 %
201930.03 %-131.3 %-124.42 %
201835.06 %-261.43 %-258.52 %
201743.23 %-188.91 %-195.41 %
201625.04 %-389.49 %-321.64 %
2015-30.1 %0 %0 %
2014-30.1 %0 %0 %
2013-30.1 %0 %0 %
2012-30.1 %0 %0 %
2011-30.1 %0 %0 %
2010-30.1 %0 %0 %
200910.34 %-1,372.41 %-2,313.79 %
2008-30.1 %0 %0 %
2007-30.1 %0 %0 %
200690.23 %-175.94 %363.53 %
200597.95 %-43.93 %-41.07 %
200497.04 %-689.66 %-1,386.7 %
200388.27 %-857.41 %-835.19 %

Adamis Pharmaceuticals Aktienanalyse

What does Adamis Pharmaceuticals do?

Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Adamis Pharmaceuticals's Profit Margins

The profit margins of Adamis Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Adamis Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Adamis Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Adamis Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Adamis Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Adamis Pharmaceuticals stock

How much profit has Adamis Pharmaceuticals made this year?

Adamis Pharmaceuticals has made 6.12 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -180% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Adamis Pharmaceuticals publish its earnings?

Adamis Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Adamis Pharmaceuticals?

The profits of Adamis Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Adamis Pharmaceuticals?

You can learn more about the earnings of Adamis Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Adamis Pharmaceuticals pay?

Over the past 12 months, Adamis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adamis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adamis Pharmaceuticals?

The current dividend yield of Adamis Pharmaceuticals is .

When does Adamis Pharmaceuticals pay dividends?

Adamis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adamis Pharmaceuticals?

Adamis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adamis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adamis Pharmaceuticals located?

Adamis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adamis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adamis Pharmaceuticals from 10/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2024.

When did Adamis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Adamis Pharmaceuticals in the year 2023?

In the year 2023, Adamis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adamis Pharmaceuticals pay out the dividend?

The dividends of Adamis Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Adamis Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Adamis Pharmaceuticals

Our stock analysis for Adamis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adamis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.